The professional's guide to product selection
The professional's guide to product selection
Straight-pronged adult nasal cannula.
The AeroChamber Plus® Flow-Vu valved holding chamber (VHC) is a medical device designed to help improve delivery of pressurised metered dose inhaler (puffer) medications to the lungs. The successor to the popular AeroChamber® Plus spacer, the Flow-Vu* Inhalation Indicator provides assurance that patients are using their inhaler with spacer correctly as it moves as they inhale and only if there is a proper seal, and so can be used to count the number of breaths taken.
Available with a mask or mouthpiece, in a range of sizes: from infant to adult.
Stockists: GP Supplies, Mistry Medical Supplies.
Long-acting selective beta2 agonist with corticosteroid.
AirFluSal 125
• Adult for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal 250
• Over 18 years for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal Forspiro
• Adult for severe asthma and COPD: one inhalation twice a day.
Short-acting selective beta2 agonist.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
This pocket-sized peak flow meter is suitable for both adults and children and features a patented tamper-proof zoning system that allows safe and accurate self-management. It has been calibrated by hand to ensure consistency. This EU scale version measures peak expiratory flow in the range 60–720 l/min. It is suitable for adults and children and recommended only for single-patient use. It includes optional zoning markers and is lightweight and compact.
Sedating antihistamine.
By mouth for symptomatic relief of allergy such as hay fever, urticaria, food allergy, drug reactions, relief of itch associated with chickenpox.
• Child 1–23 months: 1 mg, twice daily.
• Child 2–5 years: 1 mg, every 4–6 hours, maximum 6 mg daily.
• Child 6–11 years: 2 mg, every 4–6 hours, maximum 12 mg daily.
• Over 12 years: 4 mg, every 4–6 hours, maximum 24 mg daily
• Elderly: 4 mg, every 4–6 hours, maximum 12 mg daily.
Emergency treatment of anaphylactic reactions or symptomatic relief of allergy by intramuscular injection or by intravenous injection over 1 minute.
• Child 1–5 months: 250 mcg/kg (maximum per dose 2.5 mg), max 4 doses daily
• Child 6 months–5 years: 2.5 mg, maximum 4 doses per day.
• Child 6–11 years: 5 mg, maximum 4 doses per day.
• Over 12 years: 10 mg, maximum 4 doses per day.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
For the prophylaxis of asthma.
• Over 12 years: 160 micrograms once daily; reduced to 80 micrograms once daily, if control maintained; increased if necessary up to 320 micrograms twice daily, in severe asthma.
Aminophylline is used to widen the bronchi and reduce the amount of swelling and mucous in the lungs.
Slow intravenous injection
Severe acute asthma or acute exacerbation of COPD in patients not previously treated with theophylline, by slow intravenous injection over at least 20 minutes (with close monitoring):
• Child: 5 mg/kg (maximum per dose 500 mg), to be followed by intravenous infusion
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.
Severe acute exacerbation of COPD in patients not previously treated with theophylline
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.
By intravenous infusion
Severe acute asthma:
• Child under 12 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration.
• Over 12 years: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma–theophylline concentration.
Severe acute exacerbation of COPD by intravenous infusion:
• Adult: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma-theophylline concentration.
By mouth using modified-release medicines
Chronic asthma:
• Child (body weight 40kg and above): 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.
Reversible airway obstruction:
• Adult (body weight 40kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma theophylline concentration.